Northstrive Biosciences focuses on innovative biotechnological solutions aimed at advancing healthcare and improving patient outcomes. The company specializes in the development of cutting-edge therapies that leverage advanced biological research and methodologies. Their pipeline includes a range of products designed to address unmet medical needs, utilizing proprietary techniques to enhance drug efficacy and safety. Northstrive's commitment to scientific excellence is evident in their rigorous research and development processes, which are aimed at translating scientific discoveries into viable therapeutic options.

The technologies employed by Northstrive Biosciences encompass a variety of approaches, including but not limited to, targeted drug delivery systems and novel biomolecular engineering. These technologies are designed to optimize the therapeutic potential of their products, ensuring that they are both effective and tailored to specific patient populations. By integrating advanced analytics and data-driven methodologies, Northstrive aims to streamline the drug development process, ultimately bringing innovative treatments to market more efficiently. Their focus on collaboration with academic and industry partners further enhances their ability to push the boundaries of current scientific knowledge and translate it into practical applications.

United States

NorthStrive Biosciences Inc., a PMGC Holdings  company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines.

Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

Northstrive Biosciences

Company Details